Inclusion Criteria:

- patients with head & neck cancer or oesophagus cancer,

- enteral nutrition with PEG at least for 14 weeks,

- cancer patients who receive a combined radio-/chemotherapy,

- start of nutritional therapy latest at beginning of the radio-/chemotherapy, body
mass index >=16 and <=30 kg/m2,0

- Kondrup Score>=3 or SGA = B/C,

- life expectancy > 6 months,

- written informed consent.

Exclusion Criteria:

- second active carcinoma,

- severe diarrhea unresponsive to codeine/loperamide,

- positive anti-HIV-test (safety reasons),

- pregnant or lactating women,

- insulin-dependent diabetes mellitus type I and II,

- patients with cardiac pacemaker,

- allergy to contents of the investigational product, to milk protein or to fish oil,

- patient has no PEG,

- participation in concurrent clinical studies with any other investigational
nutritional therapy within one months prior to start of the study,

- intake of muscle growth supportan substances (e.g. anabolics),

- additional fish oil or EPA substitution within the last 4 weeks, SGA status A (well
nourished).